CEACAM5 and neoplasm: Based on our in vivo results, 28 days after T cell infusion, mice that received dCAR-T cells showed a marked reduction in tumor burden and even complete tumor remission, which was similar to that of the conventional CAR (CEA-CAR or MSLN-CAR) T cell treatment (Fig. 3b).